Deal will see hVivo manufacture virus for use in human challenge studies
Cathal Friel
Largest individual investor understood to be an experienced life science investor
Shares in Open Orphan were up almost 5% in late morning trading in London
Company expects revenues from the contract to be recognised across 2022 and 2023
Cathal Friel to continue in executive chairman role under new management structure
Bavarian Nordic vaccine candidate used hVivo challenge trial to gather data
Open Orphan test shows shorter incubation period, effectiveness of lateral flow tests
Contract to study absorption, distribution, metabolism and excretion of drugs in body